Blueprint Medicines is collaborating with Roche on the discovery, development and commercialisation of up to five targeted cancer immunotherapies, in a deal potentially worth more than $1 billion.
{iframe}http://www.pharmatimes.com/Article/16-03-15/Roche_Blueprint_sign_1bn_cancer_immunotherapy_deal.aspx{/iframe}